2022
Gender Differences in Guideline-Directed Medical Therapy for Cardiovascular Disease Among Young Veterans
Dhruva SS, Dziura J, Bathulapalli H, Rosman L, Gaffey AE, Davis MB, Brandt CA, Haskell SG. Gender Differences in Guideline-Directed Medical Therapy for Cardiovascular Disease Among Young Veterans. Journal Of General Internal Medicine 2022, 37: 806-815. PMID: 36042086, PMCID: PMC9481764, DOI: 10.1007/s11606-022-07595-1.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyIncident coronary artery diseaseCoronary artery diseaseHeart failureMedical therapyCardiovascular diseaseWomen veteransDiagnosis of HFAldosterone system inhibitorsIncident heart failureAdverse cardiovascular outcomesClinical practice guidelinesRisk of mortalityLevel of evidenceYounger women veteransHF medicationsMultiple pharmacotherapiesAntiplatelet therapyCardiovascular outcomesYounger average ageArtery diseaseCVD careGuideline recommendationsSystem inhibitorsAdverse outcomes
2019
Association between long-term adherence to class-I recommended medications and risk for potentially preventable heart failure hospitalizations among younger adults
Chang TE, Park S, Yang Q, Loustalot F, Butler J, Ritchey MD. Association between long-term adherence to class-I recommended medications and risk for potentially preventable heart failure hospitalizations among younger adults. PLOS ONE 2019, 14: e0222868. PMID: 31545830, PMCID: PMC6756532, DOI: 10.1371/journal.pone.0222868.Peer-Reviewed Original ResearchConceptsHeart failureMedication categoriesHF hospitalizationIsosorbide dinitrateGood adherenceEnzyme inhibitors/angiotensin receptor blockersIBM MarketScan Commercial DatabaseAngiotensin receptor blockersHeart failure hospitalizationReduced ejection fractionAldosterone receptor antagonistsMarketScan Commercial DatabaseLong-term adherencePoor health outcomesEffectiveness of interventionsLong-term managementGood adherersHF medicationsHospitalization 3Failure hospitalizationInsured adultsBeta blockersEjection fractionInitial diagnosisOutpatient settingOptimal Medical Therapy in Heart Failure: Reasons for Lack of Medication Titration in the GUIDE IT Trial
Fiuzat M, Alemayehu W, Ezekowitz J, Westerhout C, Whellan D, Mulder H, Ahmad T, Adams K, Pina I, Anstrom K, Cooper L, Alhanti B, Sbolli M, Mark D, Leifer E, Felker M, O'Connor C, Januzzi J. Optimal Medical Therapy in Heart Failure: Reasons for Lack of Medication Titration in the GUIDE IT Trial. Journal Of Cardiac Failure 2019, 25: s78. DOI: 10.1016/j.cardfail.2019.07.221.Peer-Reviewed Original ResearchHeart failureMedication titrationMedical therapyMedication adjustmentsClinical outcomesTarget dosesGUIDE-IT trialOptimal medical therapyReduced ejection fractionWeeks of enrollmentEnd of studyProtocol-driven approachUse of guidelinesFree-text reasonsGDMT groupGUIDE-ITHF medicationsB-blockersNT-proBNPEjection fractionNatriuretic peptideStudy visitClinicians' decisionsIT trialSerial measurements
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply